Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:ALDX NASDAQ:CGTX NASDAQ:RKTO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.34+3.8%$4.01$1.21▼$3.81$107.19M0.68261,100 shs168,445 shsALDXAldeyra Therapeutics$1.76-5.4%$1.68$1.07▼$6.18$112.20M1.19920,422 shs1.06 million shsCGTXCognition Therapeutics$1.36-4.2%$1.12$0.25▼$3.83$127.09M1.751.04 million shs1.80 million shsRKTORocket One Inc. Common Stock$1.97-7.9%$0.84$0.49▼$2.45$40.93M0.8917.99 million shs11.82 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-6.90%-12.37%+4.76%+26.67%+140.23%ALDXAldeyra Therapeutics+13.41%+8.77%+16.98%-60.00%-20.85%CGTXCognition Therapeutics+5.19%+19.33%+10.94%+36.54%+358.21%RKTORocket One Inc. Common Stock-3.60%+57.35%+192.71%+111.88%+132.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$4.34+3.8%$4.01$1.21▼$3.81$107.19M0.68261,100 shs168,445 shsALDXAldeyra Therapeutics$1.76-5.4%$1.68$1.07▼$6.18$112.20M1.19920,422 shs1.06 million shsCGTXCognition Therapeutics$1.36-4.2%$1.12$0.25▼$3.83$127.09M1.751.04 million shs1.80 million shsRKTORocket One Inc. Common Stock$1.97-7.9%$0.84$0.49▼$2.45$40.93M0.8917.99 million shs11.82 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience-6.90%-12.37%+4.76%+26.67%+140.23%ALDXAldeyra Therapeutics+13.41%+8.77%+16.98%-60.00%-20.85%CGTXCognition Therapeutics+5.19%+19.33%+10.94%+36.54%+358.21%RKTORocket One Inc. Common Stock-3.60%+57.35%+192.71%+111.88%+132.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AALDXAldeyra Therapeutics 2.00Hold$5.50212.50% UpsideCGTXCognition Therapeutics 2.50Moderate Buy$3.33145.10% UpsideRKTORocket One Inc. Common Stock 2.00Hold$5.00153.81% UpsideCurrent Analyst Ratings BreakdownLatest RKTO, AADI, CGTX, and ALDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2026ALDXAldeyra Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026RKTORocket One Inc. Common Stock Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CGTXCognition Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CGTXCognition Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.003/25/2026RKTORocket One Inc. Common Stock D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/18/2026ALDXAldeyra Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $2.003/17/2026ALDXAldeyra Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy3/4/2026RKTORocket One Inc. Common Stock D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M4.28N/AN/A$4.29 per share1.01ALDXAldeyra TherapeuticsN/AN/AN/AN/A$0.74 per shareN/ACGTXCognition TherapeuticsN/AN/AN/AN/A$0.39 per shareN/ARKTORocket One Inc. Common StockN/AN/AN/AN/A$0.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/AALDXAldeyra Therapeutics-$33.85M-$0.46N/AN/AN/AN/A-57.34%-36.33%8/6/2026 (Estimated)CGTXCognition Therapeutics-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%8/6/2026 (Estimated)RKTORocket One Inc. Common Stock-$12.47M-$0.80N/AN/AN/AN/A-165.25%-143.61%N/ALatest RKTO, AADI, CGTX, and ALDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026RKTORocket One Inc. Common Stock-$0.1378-$0.17-$0.0322-$0.17N/AN/A5/7/2026Q1 2026ALDXAldeyra Therapeutics-$0.13-$0.06+$0.07-$0.06N/AN/A5/7/2026Q1 2026CGTXCognition Therapeutics-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A3/27/2026Q4 2025RKTORocket One Inc. Common Stock-$0.1031-$0.16-$0.0569-$0.16N/AN/A3/26/2026Q4 2025CGTXCognition Therapeutics-$0.06-$0.02+$0.04-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AALDXAldeyra TherapeuticsN/AN/AN/AN/AN/ACGTXCognition TherapeuticsN/AN/AN/AN/AN/ARKTORocket One Inc. Common StockN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ALDXAldeyra TherapeuticsN/A2.722.72CGTXCognition TherapeuticsN/A5.925.92RKTORocket One Inc. Common StockN/A3.393.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ALDXAldeyra Therapeutics59.71%CGTXCognition Therapeutics43.35%RKTORocket One Inc. Common Stock7.08%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ALDXAldeyra Therapeutics11.80%CGTXCognition Therapeutics11.11%RKTORocket One Inc. Common Stock6.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionNo DataALDXAldeyra Therapeutics1060.32 million53.20 millionOptionableCGTXCognition Therapeutics2089.50 million79.56 millionNot OptionableRKTORocket One Inc. Common Stock419.13 million17.80 millionNot OptionableRKTO, AADI, CGTX, and ALDX HeadlinesRecent News About These CompaniesROCKET ONE APPOINTS MAJOR GENERAL MALCOLM B. FROST (RET.June 3 at 8:22 AM | prnewswire.comRKTO Rocket One Inc.May 30, 2026 | seekingalpha.comRocket One Inc.May 30, 2026 | cnn.comRocket One Inc. Common Stock (NASDAQ:RKTO) Stock Rating Upgraded by Wall Street ZenMay 30, 2026 | americanbankingnews.comFrom biotech to orbit: Rocket One's AI and space re-brand sends shares flyingMay 29, 2026 | msn.comRocket One Rebrands From Hoth, Refocusing on Space ComputingMay 28, 2026 | theglobeandmail.comRKTO Stock Extends Rally After Landing Its First AI Catalyst – Retail Bulls Are Chasing An AI-Space DreamMay 28, 2026 | finance.yahoo.comHoth Therapeutics’ pivot to AI in space sees stock rocket after rebrandMay 28, 2026 | fiercebiotech.comFHoth Therapeutics, Inc.: Hoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra ...May 27, 2026 | finanznachrichten.deHoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation ...May 27, 2026 | tmcnet.comRocket One Rebrand Marks Strategic Shift Toward Space AI Chip and Orbital Computing Markets (RKTO)May 27, 2026 | finance.yahoo.comHOTH’s Pivot From Biotech To Space Tech Sparks Massive Rally In Stock – Retail Underlines Importance Of Securing Fresh DealsMay 27, 2026 | finance.yahoo.comHoth Therapeutics Becomes Rocket One Inc. (Nasdaq: RKTO), Targeting the Space Economy with Next-Generation Nanomagnetic AI Chip Technology and Ultra-Low-Power, Radiation-Tolerant Computing for Space and Defense ApplicationsMay 27, 2026 | prnewswire.comHoth Therapeutics (HOTH) Projected to Post Quarterly Earnings on WednesdayMay 27, 2026 | americanbankingnews.comHoth Therapeutics Awarded U.S. Patent for Cancer-Fighting HT-KIT Oncology PlatformMay 26, 2026 | prnewswire.comHoth Therapeutics, Inc.: AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of ...May 20, 2026 | finanznachrichten.deHoth Therapeutics shares slide after shift toward AI semiconductor strategy (HOTH)May 20, 2026 | msn.comAI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor ArchitectureMay 19, 2026 | prnewswire.comHoth Therapeutics Launches Rocket One Space Subsidiary InitiativeMay 6, 2026 | tipranks.comHoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer PatientsMay 5, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRKTO, AADI, CGTX, and ALDX Company DescriptionsAadi Bioscience NASDAQ:AADI$4.34 +0.16 (+3.83%) As of 06/3/2026Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Aldeyra Therapeutics NASDAQ:ALDX$1.76 -0.10 (-5.38%) Closing price 04:00 PM EasternExtended Trading$1.78 +0.02 (+1.42%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.Cognition Therapeutics NASDAQ:CGTX$1.36 -0.06 (-4.23%) Closing price 04:00 PM EasternExtended Trading$1.40 +0.04 (+2.94%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Rocket One Inc. Common Stock NASDAQ:RKTO$1.97 -0.17 (-7.94%) As of 04:00 PM EasternHoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
